Last updated: February 23, 2026
What is NDC 66993-0188?
The National Drug Code (NDC) 66993-0188 identifies a specific drug product. This NDC corresponds to Aflibercept (Eylea) prefilled syringe 2 mg/0.05 mL, marketed by Regeneron Pharmaceuticals. It is used for treating conditions such as wet age-related macular degeneration, diabetic macular edema, and other retinal diseases.
Market Overview
Market Size and Growth
- U.S. Wet AMD Market Size: Estimated at $4.5 billion in 2022, projected to grow at roughly 5-7% annually through 2027 due to aging demographics and increased diagnosis rates [1].
- Key Competitors: Lucentis (ranibizumab), Beovu (brolucizumab), off-label use of off-label off-label anti-VEGF agents.
- Market Penetration: Eylea dominates approximately 70% of market share among anti-VEGF treatments for retinal diseases [2].
Regulatory and Reimbursement Status
- FDA Approval: First approved in 2011.
- Insurance & Reimbursement: Widely covered by Medicare, Medicaid, and private insurers.
- Pricing Environment: Increased focus on value-based pricing and biosimilars' entry expected to influence pricing strategies.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per injection |
Notes |
| 2018 |
$1,850 |
Stable, with minimal fluctuations |
| 2020 |
$1,950 |
Slight increase, reflecting inflation adjustments |
| 2022 |
$2,100 |
Price increases continued, driven by market factors |
Current Treatment Cost
- Per-visit cost: Approximately $2,100–$2,200.
- Annual treatment cost: Averaging 8-12 injections annually, leading to $16,800–$26,400 per patient.
Future Price Drivers
- Biosimilar Entry: Pending biosimilars anticipated by 2024 could reduce prices by 15-30%.
- Regulatory Changes: CMS and private payers increasing push for cost containment.
- Market Competition: Introduction of alternative treatments like faricimab could pressure Eylea prices.
- Manufacturing Costs: Innovation in delivery mechanisms and manufacturing efficiencies may initially lower prices.
Price Projection (2023–2027)
| Year |
Estimated Price per Injection |
Comment |
| 2023 |
$2,150 |
Stable, marginal inflationary adjustments |
| 2024 |
$2,050–$2,100 |
Biosimilar market entry begins to influence prices |
| 2025 |
$1,900–$2,000 |
Biosimilars gain market share, exerting downward pressure |
| 2026 |
$1,850–$1,950 |
Market stabilization, further biosimilar competition |
| 2027 |
$1,800–$1,900 |
Continued price erosion expected |
Comparative Analysis with Similar Products
| Product |
Price per Injection |
Market Share |
Approval Date |
| Lucentis |
~$2,200 |
20–25% |
2006 |
| Beovu |
~$2,200 |
5–10% |
2019 |
| Faricimab |
~$1,950 |
Limited (2022) |
2022 |
Strategic Implications
- Pricing Erosion: Entry of biosimilars and newer therapies anticipates a reduction in Eylea’s per-unit price.
- Market Share Loyalty: Eylea’s established efficacy and adherence to treatment protocols provide some pricing power, particularly in high-volume ophthalmology clinics.
- Cost Management: Payers incentivize switching to biosimilars, urging manufacturers to consider value-based pricing models.
Key Takeaways
- NDC 66993-0188 (Eylea prefilled syringe 2 mg/0.05 mL) dominates the retinal disease market with a robust market share.
- Prices have incrementally increased over the past five years but are projected to decline gradually through 2027 due to biosimilar competition.
- The current average wholesale price per injection is approximately $2,100, with annual treatment costs ranging from $16,800 to $26,400.
- Biosimilar entry expected by 2024 will likely reduce prices by 15–30%, influencing market dynamics.
- Innovation in treatment delivery and evolving reimbursement policies will continue to shape pricing strategies.
FAQs
1. When are biosimilars for Eylea expected to enter the market?
Biosimilars are projected to launch around 2024, with regulatory approvals pending.
2. How will biosimilar entry affect Eylea’s market share?
Biosimilars are expected to capture 30–50% of the market within the first two years post-launch, pressuring Eylea’s pricing and volume.
3. What is the typical treatment regimen for Eylea?
Patients usually receive injections every 8 to 12 weeks, with treatment duration varying based on disease response.
4. How does Eylea’s pricing compare to similar drugs?
Eylea’s prices are comparable to Lucentis and Beovu; however, pricing strategies may vary with competitive pressures and negotiations.
5. What factors could accelerate or slow down price reductions?
Regulatory changes, payer policies, new therapeutic options, and manufacturing efficiencies influence the pace of price adjustments.
References
[1] IQVIA. (2022). US Ophthalmology Market Report.
[2] Evaluate Pharma. (2022). Ophthalmology drugs market analysis.
